Trinity Biotech ROA 2006-2018 | TRIB
Current and historical return on assets (ROA) values for Trinity Biotech (TRIB) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Trinity Biotech ROA for the three months ending September 30, 2018 was 1.30%.
| Trinity Biotech ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2018-09-30 | $-0.04B | $0.18B | -21.44% |
| 2018-06-30 | $-0.04B | $0.19B | -20.31% |
| 2018-03-31 | $-0.04B | $0.20B | -19.13% |
| 2017-12-31 | $-0.04B | $0.19B | -17.67% |
| 2017-09-30 | $-0.10B | $0.25B | -40.20% |
| 2017-06-30 | $-0.10B | $0.25B | -36.36% |
| 2017-03-31 | $-0.10B | $0.25B | -32.65% |
| 2016-12-31 | $-0.10B | $0.25B | -30.42% |
| 2016-09-30 | $0.00B | $0.36B | 0.83% |
| 2016-06-30 | $0.02B | $0.36B | 4.45% |
| 2016-03-31 | $0.02B | $0.36B | 4.73% |
| 2015-12-31 | $0.02B | $0.36B | 6.64% |
| 2015-09-30 | $0.02B | $0.36B | 7.63% |
| 2015-06-30 | $0.02B | $0.36B | 5.52% |
| 2015-03-31 | $0.02B | $0.25B | 6.63% |
| 2014-12-31 | $0.02B | $0.24B | 6.76% |
| 2014-09-30 | $0.02B | $0.24B | 7.31% |
| 2014-06-30 | $0.01B | $0.24B | 4.37% |
| 2014-03-31 | $0.01B | $0.23B | 4.54% |
| 2013-12-31 | $0.01B | $0.23B | 4.68% |
| 2013-09-30 | $0.01B | $0.22B | 4.36% |
| 2013-06-30 | $0.02B | $0.20B | 8.07% |
| 2013-03-31 | $0.02B | $0.20B | 8.27% |
| 2012-12-31 | $0.02B | $0.20B | 8.50% |
| 2012-09-30 | $0.02B | $0.19B | 8.80% |
| 2012-06-30 | $0.02B | $0.18B | 9.05% |
| 2012-03-31 | $0.02B | $0.18B | 9.26% |
| 2011-12-31 | $0.02B | $0.17B | 9.48% |
| 2011-09-30 | $0.02B | $0.17B | 9.62% |
| 2011-06-30 | $0.02B | $0.17B | 9.19% |
| 2011-03-31 | $0.06B | $0.17B | 38.87% |
| 2010-12-31 | $0.06B | $0.16B | 40.40% |
| 2010-09-30 | $0.06B | $0.16B | 41.74% |
| 2010-06-30 | $0.06B | $0.15B | 43.88% |
| 2010-03-31 | $0.01B | $0.13B | 9.14% |
| 2009-12-31 | $0.01B | $0.13B | 9.27% |
| 2009-09-30 | $-0.07B | $0.13B | -56.59% |
| 2009-06-30 | $-0.08B | $0.13B | -49.83% |
| 2009-03-31 | $-0.08B | $0.13B | -44.19% |
| 2008-12-31 | $-0.08B | $0.13B | -40.21% |
| 2008-09-30 | $-0.04B | $0.22B | -17.17% |
| 2008-06-30 | $-0.04B | $0.22B | -17.04% |
| 2008-03-31 | $-0.04B | $0.21B | -16.03% |
| 2007-12-31 | $-0.04B | $0.22B | -19.72% |
| 2007-09-30 | $0.01B | $0.25B | 4.31% |
| 2007-06-30 | $0.01B | $0.25B | 5.92% |
| 2007-03-31 | $0.01B | $0.00B | 4.85% |
| 2006-12-31 | $0.00B | $0.25B | 3.23% |
| 2006-09-30 | $0.00B | $0.25B | 2.78% |
| 2006-06-30 | $0.00B | $0.00B | 2.20% |
| 2006-03-31 | $0.01B | $0.00B | 3.82% |
| 2005-12-31 | $0.01B | $0.19B | 2.94% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.066B | $0.099B |
| Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $126.543B | 19.40 |
| Abbott Laboratories (ABT) | United States | $126.526B | 25.64 |
| Stryker (SYK) | United States | $64.420B | 24.28 |
| Boston Scientific (BSX) | United States | $51.491B | 26.02 |
| Baxter (BAX) | United States | $35.393B | 22.86 |
| Zimmer Biomet Holdings (ZBH) | United States | $23.875B | 15.48 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.038B | 0.00 |
| ResMed (RMD) | United States | $14.846B | 28.31 |
| Perrigo (PRGO) | Ireland | $8.596B | 13.05 |
| Bio-Rad Laboratories (BIO) | United States | $8.274B | 52.91 |
| Canopy Growth (CGC) | Canada | $8.174B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.270B | 19.88 |
| Aurora Cannabis (ACB) | Canada | $6.172B | 33.68 |
| Haemonetics (HAE) | United States | $5.727B | 50.36 |
| ICU Medical (ICUI) | United States | $4.968B | 27.68 |
| Insulet (PODD) | United States | $4.838B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $4.052B | 0.00 |
| Hutchison China MediTech (HCM) | China | $4.010B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.990B | 0.00 |
| Neogen (NEOG) | United States | $3.294B | 49.88 |
| NuVasive (NUVA) | United States | $3.166B | 29.46 |
| National Vision Holdings (EYE) | United States | $3.024B | 58.49 |
| Quidel (QDEL) | United States | $2.507B | 32.68 |
| Aphria (APHA) | $2.433B | 0.00 | |
| NxStage Medical (NXTM) | United States | $1.933B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.409B | 19.95 |
| AtriCure (ATRC) | United States | $1.241B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.058B | 1524.50 |
| VAREX IMAGING (VREX) | United States | $0.999B | 20.07 |
| Meridian Bioscience (VIVO) | United States | $0.823B | 26.23 |
| Surmodics (SRDX) | United States | $0.794B | 121.41 |
| OraSure Technologies (OSUR) | United States | $0.772B | 43.48 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.756B | 24.24 |
| MacroGenics (MGNX) | United States | $0.740B | 0.00 |
| Cerus (CERS) | United States | $0.716B | 0.00 |
| PetIQ (PETQ) | United States | $0.705B | 20.03 |
| Lantheus Holdings (LNTH) | United States | $0.625B | 19.34 |
| Omeros (OMER) | United States | $0.619B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.540B | 26.52 |
| Owens & Minor (OMI) | United States | $0.535B | 6.05 |
| Insys Therapeutics (INSY) | United States | $0.527B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.521B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.444B | 0.00 |
| Evolus (EOLS) | United States | $0.403B | 0.00 |
| Quanterix (QTRX) | United States | $0.376B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.332B | 21.45 |
| Cytosorbents (CTSO) | United States | $0.313B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.264B | 0.00 |
| Surface Oncology (SURF) | United States | $0.225B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.214B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.204B | 275.00 |
| Chimerix (CMRX) | United States | $0.172B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.146B | 0.00 |
| Fonar (FONR) | United States | $0.141B | 7.06 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.123B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.106B | 0.00 |
| United-Guardian (UG) | United States | $0.080B | 16.85 |
| Female Health (VERU) | United States | $0.075B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.070B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.053B | 0.00 |
| Neurotrope (NTRP) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.043B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.029B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.018B | 0.00 |
| Senestech (SNES) | United States | $0.017B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
